{"id":180535,"date":"2024-01-15T13:23:47","date_gmt":"2024-01-15T19:23:47","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/01\/cancer-vaccine-safe-induces-t-cell-responses-for-kras-mutated-tumors"},"modified":"2024-01-15T13:23:47","modified_gmt":"2024-01-15T19:23:47","slug":"cancer-vaccine-safe-induces-t-cell-responses-for-kras-mutated-tumors","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/01\/cancer-vaccine-safe-induces-t-cell-responses-for-kras-mutated-tumors","title":{"rendered":"Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/cancer-vaccine-safe-induces-t-cell-responses-for-kras-mutated-tumors2.jpg\"><\/a><\/p>\n<p>FRIDAY, Jan. 12, 2024 (HealthDay News) \u2014 For patients with immunotherapy recalcitrant KRAS-mutated tumors, the cancer vaccine ELI-002 2P is safe and induces T-cell responses, according to a study published online Jan. 9 in<em> Nature Medicine<\/em>.<\/p>\n<p>Noting that the cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using Amphiphile (Amph)-modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909), Shubham Pant, M.D., M.B.B.S., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues treated 25 patients (20 with pancreatic cancer; five with colorectal cancer) positive for minimal residual mKRAS disease after locoregional treatment in a phase 1 study involving fixed-dose Amph-Peptides-2P and ascending dose Amph-CpG-7909.<\/p>\n<p>The researchers found no dose-limiting toxicities; the recommended phase 2 dose was 10.0 mg Amph-CpG-7909. Overall, 21, 21, and six patients (84, 84, and 24 percent) had direct ex vivo mKRAS-specific T-cell responses, tumor biomarker responses, and biomarker clearance, respectively. Median relapse-free survival was 16.33 months. There was a correlation seen for efficacy with T-cell response; the median tumor biomarker reduction was \u221276.0 versus \u221210.2 percent. Median relapse-free survival was not reached compared with 4.01 months (hazard ratio, 0.14).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FRIDAY, Jan. 12, 2024 (HealthDay News) \u2014 For patients with immunotherapy recalcitrant KRAS-mutated tumors, the cancer vaccine ELI-002 2P is safe and induces T-cell responses, according to a study published online Jan. 9 in Nature Medicine. Noting that the cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using Amphiphile (Amph)-modification of G12D [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-180535","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/180535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=180535"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/180535\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=180535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=180535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=180535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}